Bhaskara, Vasantha KumarJayaram, ChaitraPriyanga, MNayaka, N H ThilakShivakumara, AAmaresh, NagarathnaMysorekar, Vijaya V2020-11-182020-11-182019-10Bhaskara Vasantha Kumar, Jayaram Chaitra, Priyanga M, Nayaka N H Thilak, Shivakumara A, Amaresh Nagarathna, Mysorekar Vijaya V. Aberrant signal transduction in Indian triple-negative breast cancer patients. Journal of Cancer Research and Therapeutics. 2019 Oct; 15(5): 1162-11660973-1482http://imsear.searo.who.int/handle/123456789/213495Aim of Study: The aim of this study is to correlate the prominin-1 or CD133 association with functional pathway markers of cancer stemness in Indian triple-negative breast cancer (TNBC) patient samples. Materials and Methods: TNBC samples were confirmed for the absence of hormone receptors (estrogen receptor–ER/progesterone receptor) and human epidermal growth factor receptor-2 or proto-oncogene neu or erbB2 or CD340 by immunohistochemical analysis. Formalin-fixed paraffin-embedded samples of patients were used to collect the total RNA. Then, one-step reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the cancer stemness-related transcript levels in the different samples. The RT-PCR products were analyzed semi-quantitatively on agarose gels. The band intensities of respective samples for different transcripts were analyzed by densitometry. Results: TNBC-confirmed samples had shown increased levels of CD133 transcript than control tissues. Further, elevated CD133 transcripts are correlated with higher transcript levels of NOTCH1/FZD7/transforming growth factor-beta receptor Type III R/patched-1 pathway mediators. Conclusions: This work has clearly indicated that there is a correlation between CD133 and functional pathways that control cancer stem cells in TNBC. These observations may indicate the possible association between cancer stemness and TNBC malignancyCancer stem cellsFZD7NOTCH1patched‑1signal transductiontransforming growth factor‑beta receptor Type III Rtriple‑negative breast cancerAberrant signal transduction in Indian triple-negative breast cancer patientsJournal ArticleIndiaDepartment of Biochemistry, RCASC, Bengaluru, Karnataka, IndiaDepartment of Biochemistry, RCASC, Bengaluru, Karnataka, IndiaDepartment of Biochemistry, RCASC, Bengaluru, Karnataka, IndiaDepartment of Biochemistry, RCASC, Bengaluru, Karnataka, IndiaDepartment of Biochemistry, RCASC, Bengaluru, Karnataka, IndiaDepartment of Biochemistry, RCASC, Bengaluru, Karnataka, IndiaDepartment of Pathology, RMCH, Bengaluru, Karnataka, India